Journal of Neural Transmission

, Volume 115, Issue 6, pp 869–878 | Cite as

Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems

  • Nicholas MacInnes
  • Mahmoud M. Iravani
  • Elaine Perry
  • Margaret Piggott
  • Robert Perry
  • Peter Jenner
  • Clive Ballard
Alzheimer's Disease and Related Disorders - Original Article


Dementia with Lewy bodies (DLB) accounts for 15–20% of the millions of people worldwide with dementia. In the current work we investigate the association between proteasome dysfunction and the development of cortical Lewy body pathology. Analysis of post-mortem cortical tissue indicated levels of the α-subunit of the 20S proteasome were significantly reduced in DLB cortex, but not Alzheimer’s, in comparison to control and this reduction correlated with both the severity and duration of dementia. Application of proteasome inhibitors to rodent cortical primary neurones in vitro and by direct injection onto rodent cholinergic forebrain neurons in vivo gave rise to dose dependent neuronal death and in rodent cortex––marked cholinergic deficits accompanied by the accumulation of inclusions that stained positive for α-synuclein and ubiquitin. These findings suggest that proteasomal abnormalities are present within cortical Lewy body disease and the experimental inhibition of proteasomal function mirrors the neuropathological changes seen within the disorder.


Dementia with Lewy bodies Ubiquitin-proteasome system Nucleus basalis magnocellularis Lactacystin α-Synuclein Ubiquitin 


  1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20:1255–1263Google Scholar
  2. Akasofu S, Kosasa T, Kimura M, Kubota A (2003) Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 472:57–63PubMedCrossRefGoogle Scholar
  3. Ballard CG, Saad K, Patel A, Gahir M, Solis M (1995) The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry 10:477–486CrossRefGoogle Scholar
  4. Ballard C, Piggott M, Johnson M, Cairns N, Perry R (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 48:868–876PubMedCrossRefGoogle Scholar
  5. Beal F, Lang A (2006) The proteasomal inhibition model of Parkinson’s disease: boon or bust? Exp Neurol 60:158–161Google Scholar
  6. Chondrogianni N, Gonos ES (2005) Proteasome dysfunction in mammalian aging: steps and factors involved. Exp Gerontol 40:931–938PubMedCrossRefGoogle Scholar
  7. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346–1349PubMedCrossRefGoogle Scholar
  8. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–1258PubMedCrossRefGoogle Scholar
  9. Fernagut PO, Chesselet MF (2004) Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17:123–130PubMedCrossRefGoogle Scholar
  10. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L (2005) Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117PubMedCrossRefGoogle Scholar
  11. Filipe sMI, Lake BD (1990) Histochemistry in Pathology, 2nd edn. Churchill Livingston, USAGoogle Scholar
  12. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23:8955–8966PubMedGoogle Scholar
  13. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K (2003) Animal models of Parkinson’s disease in rodents induced by toxins: an update. J Neural Transm Suppl 65:89–100PubMedGoogle Scholar
  14. Iravani MM, Haddon CO, Rose S, Jenner P (2006) 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 1067:256–262PubMedCrossRefGoogle Scholar
  15. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36PubMedCrossRefGoogle Scholar
  16. Lippa CF, Smith TW, Perry E (1999) Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm 106:525–535PubMedCrossRefGoogle Scholar
  17. Lohr JB, Caligiuri MP, Manley MS, Browning JA (2000) Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods. Psychopharmacology 148:171–179PubMedCrossRefGoogle Scholar
  18. Lu X, Hagg T (1997) Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J Comp Neurol 388:484–494PubMedCrossRefGoogle Scholar
  19. Martinez-Murillo R, Semenenko F, Cuello AC (1988) The origin of tyrosine hydroxylase-immunoreactive fibers in the regions of the nucleus basalis magnocellularis of the rat. Brain Res 451:227–236PubMedCrossRefGoogle Scholar
  20. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305:673–678PubMedCrossRefGoogle Scholar
  21. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW (1996) Diagnosis and management of dementia with Lewy bodies. Neurology 47:1113–1124PubMedGoogle Scholar
  22. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O’Brien J, Playfer J, Reid W, International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28PubMedCrossRefGoogle Scholar
  23. McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 297:191–194Google Scholar
  24. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2:589–594Google Scholar
  25. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P (2002a) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301–306PubMedCrossRefGoogle Scholar
  26. McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, (2002b) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13:1437–1441PubMedCrossRefGoogle Scholar
  27. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O (2002c) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett 326:155–158PubMedCrossRefGoogle Scholar
  28. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 3rd edn. Academic Press, New YorkGoogle Scholar
  29. Rideout HJ, Larsen KE, Sulzer D, Stefanis L (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78:899–908PubMedCrossRefGoogle Scholar
  30. Rideout HJ, Wang Q, Park DS, Stefanis L (2003) Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci 23:1237–1245PubMedGoogle Scholar
  31. Rideout HJ, Dietrich P, Wang Q, Dauer WT, Stefanis L (2004) Alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. J Biol Chem 279:46915–46920PubMedCrossRefGoogle Scholar
  32. Sherman MY, Goldberg AL (2001) Cellular defences against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15–32PubMedCrossRefGoogle Scholar
  33. Sumners C, Myers LM (1991) Angiotensin II decreases cGMP levels in neuronal cultures from rat brain. Am J Physiol 260: C79–C87PubMedGoogle Scholar
  34. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB 19:533–542CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Nicholas MacInnes
    • 1
  • Mahmoud M. Iravani
    • 2
  • Elaine Perry
    • 3
  • Margaret Piggott
    • 3
  • Robert Perry
    • 3
  • Peter Jenner
    • 2
  • Clive Ballard
    • 1
  1. 1.Wolfson Centre for Age-Related DiseaseKing’s College LondonLondonUK
  2. 2.Neurodegenerative Disease Research GroupKing’s College LondonLondonUK
  3. 3.Institute for Ageing and HealthUniversity of Newcastle upon Tyne, Newcastle General HospitalNewcastle upon TyneUK

Personalised recommendations